Contents
- 1 📊 Biopol Chemicals IPO GMP Today – Institutional Live Dashboard
- 2 📊 Subscription Snapshot
- 3 📊 Live Subscription Metrics
- 4 🔑 Key Highlights
- 5 📈 Capital Flow Direction
- 6 🏭 Sector and Listing Impact
- 7 📊 Scenario Analysis
- 8 📈 Listing Price Prediction Model
- 9 🏆 Positional Calls Verdict Matrix
- 10 🧠 Institutional Conclusion – Biopol Chemicals IPO Review
📊 Biopol Chemicals IPO GMP Today – Institutional Live Dashboard
🔴 LIVE UPDATE – 06 Feb 2026
Biopol Chemicals IPO GMP remains largely unchanged in the unofficial market. Dealers are reporting limited activity, with no fresh quotes or meaningful movement. Early grey market participation remains thin.
Last updated: 06 Feb 2026 | 02:30 PM IST
🧠 PositionalCalls View
GMP trends remain preliminary and should not be treated as a confirmed listing indicator. Institutional participation usually becomes visible closer to the subscription close.
📊 Market Signal
Early-stage price discovery; institutional sentiment not yet visible.
👀 What to Watch Next
- First stable GMP trend
- Institutional demand signals
- Speculative spikes
📊 Subscription Snapshot
| Category | Applications | Shares Bid | Signal |
|---|---|---|---|
| QIB | – | – | No institutional participation |
| NII | 4 | 15,600 | Very weak leveraged demand |
| Retail | 36 | 86,400 | Retail-driven participation |
| Total | 40 | 1,02,000 | Early-stage subscription |
📊 Live Subscription Metrics
| Metric | Value | Interpretation |
|---|---|---|
| Issue Price | ₹90 – ₹95 | SME valuation zone |
| GMP Range | ₹18 – ₹22 | Moderate speculative premium |
| QIB Subscription | 0.0x | No institutional demand |
| HNI Subscription | 0.2x | Very weak leverage interest |
| Retail Subscription | 1.2x | Retail-led participation |
| Total Subscription | 0.95x | Near full subscription |
🔑 Key Highlights
- Retail-driven subscription structure
- No QIB participation
- Weak HNI interest
- Moderate speculative GMP
📈 Capital Flow Direction
Capital flows are concentrated in the retail segment with negligible institutional participation. Listing momentum will likely depend on retail sentiment.
🏭 Sector and Listing Impact
SME chemical listings often show strong retail participation but limited institutional support. Absence of QIB demand increases the probability of a flat or volatile listing.
📊 Scenario Analysis
| Scenario | Probability | Outcome |
|---|---|---|
| Bull Case | 25% | Strong listing on retail momentum |
| Base Case | 50% | Listing near GMP range |
| Bear Case | 25% | Flat or weak listing |
📈 Listing Price Prediction Model
| Scenario | Price Range | Probability | Logic |
|---|---|---|---|
| Bear Case | ₹90 – ₹95 | 25% | No institutional demand |
| Base Case | ₹96 – ₹104 | 50% | GMP-driven listing |
| Bull Case | ₹104 – ₹112 | 25% | Retail momentum |
🏆 Positional Calls Verdict Matrix
| Dimension | Assessment |
|---|---|
| Overall Verdict | High Risk – High Reward |
| Short-term Outlook | Moderate Listing Potential |
| Long-term Outlook | Weak Fundamental Moat |
| Suitable Investors | High-risk SME participants |
| Not Suitable For | Conservative investors |
🧠 Institutional Conclusion – Biopol Chemicals IPO Review
Biopol Chemicals IPO remains a retail-driven SME issue with no institutional participation. Listing performance may remain sentiment-driven unless institutional demand improves.
Related Analysis
Latest IPO analysis on PositionalCalls
Official Sources
Shubham tracks Indian equity markets with a focus on banking stocks, insurance companies, and long-term value investing. PositionalCalls was built to give independent investors the same quality of research that institutional desks produce — in plain language, with no brokerage bias and no paid promotions. All analysis is sourced from RBI, SEBI, NSE/BSE filings, and company annual reports.